P-;G Health stock tumbles 4% despite standalone net profit rises 224% yoy in March 2022 quarter

6 May 2022 , 09:20 AM

Procter & Gamble Health Limited announced its financial results for the quarter ended March 31, 2022.

The Company has delivered total sales of Rs262 crore for the quarter ended March 31, 2022 vs Rs214 crore, up by 23% vs year ago. The Profit After Tax (PAT) was Rs51.2 crore, up by 224% vs year ago.

Increase in PAT is driven by higher sales and lower marketing and depreciation charge vs same period last year. Sales for the nine-month period ending March 31, 2022, were Rs803 crore, vs Rs710 crore up 13% vs a year ago. PAT for nine-month period is Rs151 crore Vs Rs143 crore a year ago, despite high inflationary pressures.

At around 9:21 AM, Procter & Gamble Health stock was trading at Rs4267.05 per piece lower by 4.21% on the BSE.

Milind Thatte, Managing Director, P&G Health India, said, “We have been able to register consistent growth in revenue and earnings in recent quarters. Our strong portfolio of products that address the increasing demand for daily supplementation and a renewed focus on expanded reach and improved productivity continue to form the pillars of our strategy. We will leverage our strengths in medico-marketing, technology and distribution, in order to better serve the consumers and customers who count on us.”

“We continue our efforts in promoting consumer education, raising awareness around women’s health and overall health and wellness. This year, we launched ‘Women in Healthcare’ summit as a platform to encourage more women to join the healthcare and pharma sectors.

We continue to strengthen and expand our projects under SEHAT, our CSR program that aims at contributing to building a healthier India. Recently, we partnered with Apnalaya, to extend our support to the urban poor and provide care to underprivileged pregnant women, new mothers and newborns,” he added.